Xcout Intel
Arrivo BioVentures, LLC competitors & alternatives
The 12 closest competitors and alternatives to Arrivo BioVentures, LLC among biotechnology companies — ranked by similarity to what Arrivo BioVentures, LLC actually does, not by market-cap band.
Subscribe to see Arrivo BioVentures, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Arrivo BioVentures, LLC
Arrivo BioVentures, LLC is a biopharmaceutical holding company that provides management oversight, funding, and intellectual property development for subsidiaries targeting hard-to-treat diseases. The company's clinical-stage pipeline includes drug candidates for major depressive disorder and severe acute pancreatitis.
Arrivo BioVentures, LLC at a glance
Arrivo BioVentures, LLC is a biotechnology company headquartered in United States. It has raised at least $88.5M across the 2 funding rounds on record. Its most recent funding round raised $43.2M in November 2023. Xcout tracks 10 named people at Arrivo BioVentures, LLC, including Kelly Abernathy (Chief Operating Officer).
Arrivo BioVentures, LLC leadership
- Kelly AbernathyChief Operating Officer
- Karen AdamsChief Financial Officer
- Joel RaskinChief Medical Officer
- Stephen E. ButtsChief Executive Officer
- Greg RigdonSenior Vice President Scientific Affairs
- John HixonHead of Corporate Development
4 more named people on record for Arrivo BioVentures, LLC, with roles, board committees and tenure — see the full roster →
Arrivo BioVentures, LLC funding rounds
At least $88.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $43.2M | — | |
| Series B | $45.3M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Arrivo BioVentures, LLC competitors
Ranked by semantic similarity — how close each company is to Arrivo BioVentures, LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Neurawell Therapeutics is a clinical-stage research and development company that develops central nervous system (CNS) treatments. It focuses on addressing unmet medical needs for patients suffering from conditions such as depression, major depressive disorder, treatment-resistant depression, anxiety, and neurological disorders like Parkinson's disease.
Biotech
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Biotech
Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company. It is dedicated to developing rapid-acting treatments for neuropsychiatric diseases.
Similar biotechnology company
Evecxia, Inc. is a holding and therapeutics company founded in 2013 and based in North Carolina, focusing on drug pipelines, patents, and clinical trials for neuropsychiatric conditions.
Similar biotechnology company
VivaMed BioPharma is a clinical-stage biopharmaceutical company that develops new chemical entities and repurposed drugs. It serves the healthcare and research sectors by advancing therapies across neurology, pain, psychiatry, pulmonology, and rheumatology through global partnerships and operator-led development.
Biotech
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Biotech
Beyond Bio is a biotechnology company that researches and develops novel therapeutics for various oncological and neurological conditions, including pancreatic cancer, colorectal cancer, glioblastoma, blood cancer, lung cancer, and Alzheimer's disease. The company also develops proprietary drug delivery technologies to support its therapeutic pipeline.
Similar biotechnology company
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Biotech
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Similar biotechnology company
Aptinyx Inc. is an Evanston, Illinois-based clinical-stage biotechnology company focused on discovering and developing innovative therapies for challenging disorders of the brain and nervous system.
Similar biotechnology company
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Arrivo BioVentures, LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Arrivo BioVentures, LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →